- Home ›
- About us ›
- Our people ›
- Academic and research staff ›
- Profile Page
Dr Sandra Appiah
-
Biography &
QualificationsBSc MSc PGCert PhD
Languages Spoken
-
Learning &
Teaching Interests- Bioanalytical techniques
- Biochemistry
- Phytochemistry
- Molecular biology
- Research methods
-
Research Outputs &
Interests- The identification of hCGβcf from pregnancy urine using MALDI mass spectrometry for the detection of Downs syndrome
- Natural product research: The effects of anti-inflammatory and anti-cancer natural products on nuclear factor kappaB transcriptional factor and other pro-inflammatory proteins.
Publication Feed
Betulinic acid-doxorubicin drug combination synergistically supresses cell viability and enhances apoptotic death in acute myeloid leukaemia cell lines by increasing Bax/Bcl-2 ratio
Vu, Milan and Kassouf, Nick and Bell, Celia M. and Appiah, Sandra S. (2018) Betulinic acid-doxorubicin drug combination synergistically supresses cell viability and enhances apoptotic death in acute myeloid leukaemia cell lines by increasing Bax/Bcl-2 ratio. In: NCRI Cancer Conference (2018), 04-06 Nov 2018, Glasgow, Scotland.
The combination of curcumin and doxorubicin shows a selective cytotoxic effect on acute myeloid leukaemia cell line
Hasan, Noor and Roberts, Helen and Ghali, Lucy and Appiah, Sandra S. (2018) The combination of curcumin and doxorubicin shows a selective cytotoxic effect on acute myeloid leukaemia cell line. In: NCRI Cancer Conference (2018), 04-06 Nov 2018, Glasgow, Scotland.
α-Mangostin, singly and in combination with Doxorubicin, as pro-apoptotic agents and protein kinase inhibitors In the AML cell line, Molm13
Osemeke, Cynthia and Garelick, Hemda and Wen, Xuesong and Appiah, Sandra S. (2018) α-Mangostin, singly and in combination with Doxorubicin, as pro-apoptotic agents and protein kinase inhibitors In the AML cell line, Molm13. In: EACR Conference Series: A matter of Life or Death. from Basic cell Death Mechanism to Novel cancer Treatment, 1th-3rd Feb. 2018, Amstardam, Netherlands.
Doxorubicin combined with Alpha Mangostin as pro-apoptotic agents and as potential kinase inhibitors of acute Myeloid Leukaemia
Osemeke, Cynthia and Garelick, Hemda and Wen, Xuesong and Appiah, Sandra S. (2017) Doxorubicin combined with Alpha Mangostin as pro-apoptotic agents and as potential kinase inhibitors of acute Myeloid Leukaemia. In: 2017 NCRI Cancer Conference, 5-8 Nov 2017, Liverpool, UK.
View more publicationsPotential interactions of Alpha Mangostin with Doxorubicin as potential Kinase inhibitors on myeloid leukaemic cell line
Osemeke, Cynthia and Garelick, Hemda and Wen, Xuesong and Appiah, Sandra S. (2017) Potential interactions of Alpha Mangostin with Doxorubicin as potential Kinase inhibitors on myeloid leukaemic cell line. In: 2017 Middlesex University Research Student Summer Conference, 28-29 June 2017, London, UK.
-
Funded Research &
Knowledge Exchange Projects -
Engagement &
Impact
In this section
- What we do
-
Our people
- Chancellor
- Vice-Chancellor and Executive
- Professional services
-
Academic and research staff
- Amietta, Santiago
- Anastasiades, Mario
- Baker, Tremaine
- Bannerman, Christopher
- Barrett, Brenda
- Bishop, Chris
- Bryant, Lizi
- Carnac, Helen
- Carr, Sarah
- Charalambidou, Anna
- Cockburn, Emma
- Cohan, Robert
- DeMarco, Jeffrey
- Dilmperi, Athina
- Doddapaneni, krishna
- Espin, Antonio
- Gandini, Alessandro
- Gomez, Lorenzo
- Howarth, Mike
- Ioana Serghiuta
- Jacobs, Catherine
- Kazim, Raza
- Kelly, Michael
- Kierans, Lauren
- Kleiman, Paul
- Klika, Deborah
- Lee, Hsing-Fen
- Loizidou, Erika
- Long, Ellouise
- Longstaff, Fran
- McGrath, Martin
- Morrison, Scott
- Nichols, Barry
- Nikolou-Walker, Elda
- O'Donnell, Aiden
- Popescu, Andrei
- Reynolds, Gemma
- Rix, Oliver
- Smith, Martin C.
- Timmermans, Martijn
- Tirimo, Martino
- Tolmer, Mireille
- Weaver, Timothy
- Webb, Neville
- Windridge, David
- Board of Governors
- Student charter
- Honorary graduates
- Our stories: Made in Middlesex
- Our reputation and impact
- Our community
- Our alumni
- Careers at Middlesex
- Our policies
